10 results
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... Pap tests are normal ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... candida #mucosal #IDSA ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
APS), Secondary prevention ... Erythematosus #SLE #CNS #neurology ... #rheumatology # ... cerebritis #diagnosis #management ... #treatment
IDSA Recommendations for Preventing and Managing Cryptosporidiosis in HIV-AIDS
Preventing Chronic Cryptosporidiosis:
 • Because chronic cryptosporidiosis occurs
IDSA Recommendations ... • Aggressive oral ... Cryptosporidiosis #IDSA ... #Prevention #Treatment ... #infections #HIVAIDS
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... specialist) + ART • Oral ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS
Triptan Selection - Migraine Management
Choosing triptans:
 • Reponse to given triptan do not predict to others
Selection - Migraine Management ... • Fast-acting oral ... response: • Consider preventive ... #treatment #neurology ... selection #headache #neurology
IDSA Recommendations for Treating Herpes Simplex Virus (HSV) Infections in HIV-AIDS
Treating Orolabial Lesions (Duration: 5–10 days)
IDSA Recommendations ... regress, change to oral ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS
IDSA Recommendations for Treating Coccidiodomycosis in HIV-AIDS
Treating Mild Infections (Such As Focal Pneumonia or asymptomatic patients
IDSA Recommendations ... with positive serology ... #Prevention #Treatment ... #management #opportunistic ... #infections #HIVAIDS
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
bradycardia, urinary retention ... CSF PROTEIN - NORMAL ... Treatment: • Plasmapheresis ... Syndrome #diagnosis #management ... #treatment #neurology
Neurosarcoidosis - Diagnosis and Treatment
 • 5 to 40% of sarcoidosis, Heterogeneous, often inaugural
 • Central
Diagnosis and Treatment ... paucisymptomatic: Oral ... 3-5 days then oral ... #management #neurology ... #rheumatology